Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?

OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking. We aimed to clarify the outcomes of repeated MPA...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamagami, Wataru, Susumu, Nobuyuki, Makabe, Takeshi, Sakai, Kensuke, Nomura, Hiroyuki, Kataoka, Fumio, Hirasawa, Akira, Banno, Kouji, Aoki, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823982/
https://www.ncbi.nlm.nih.gov/pubmed/29400014
http://dx.doi.org/10.3802/jgo.2018.29.e21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823982/
https://www.ncbi.nlm.nih.gov/pubmed/29400014
http://dx.doi.org/10.3802/jgo.2018.29.e21

Ejemplares similares